GlydeTM CGM is a miniature, long term, implantable continuous glucose monitoring system for both Type 1 and insulin-dependent Type2 diabetes patients.  The system includes a miniature sensor implanted under the skin and an external wearable device.  The wearable device reads the glucose signal from the implant and provides basic display and alarms.  Data is additionally sent to a smartphone app for additional display and control functions.


Glucose detection is based on a proprietary fluorescent Biosensor protein having two fluorophore groups and a glucose binding domain.  Utilizing the Fluorescent Resonant Energy Transfer (FRET) effect, this biosensor changes its fluorescent emission upon selectively binding a glucose molecule.  As the binding is reversible, the percentage of biosensor molecules which are found at the bound state at a given moment is determined by the glucose concentration in the medium.   Utilizing the FRET effect, two fluorescent signals are detected in every measurement event, where one signal is glucose-sensitive and the other is glucose-insensitive.  By taking the ratio between the two fluorescent signals a robust measurement is obtained, which is insensitive to changes in biosensor concentration or exact measurement conditions.  The patent-pending Biosensor  was optimized by GluSense for best response in the full physiological range of glucose values with special emphasis on the low glucose values, which are most important in order to prevent hypoglycemia.


Maintaining sensor functionality for the long term is challenging using any sensing technology, as the active material, enzyme or fluorescent molecule, decays in the body over just a few weeks.  GluSense’s innovative technology utilizes engineered live human cells to continuously replenish the Biosensor in-situ, verifying that fresh biosensor is always available.  A tiny amount of the cells are encapsulated inside a compartment of the implant, effectively separated from the body by a selective membrane which allows only small molecules, e.g. glucose and Oxygen, to diffuse in and out.  The membrane thus protects the cells from the immune system of the patient which would otherwise destroy the cells.   


Glyde CGM is composed of a miniature implant and an external wearable device.  The implant does not contain a battery and is energized in real time by the wearable device using RF.  The optical measurement is performed by the combined operation of the implant and the wearable device and is repeated every several seconds.  The raw data is analyzed  by the wearable device using advanced algorithms, translated to glucose levels and update on the wearable’s display every several minutes.  Glucose data will be sent to a smartphone application for additional display, charting and cloud upload.